by | Feb 24, 2025 | Lupus Foundation of America, News & Events
Conduit Pharmaceuticals and Charles River Laboratories have announced a partnership to evaluate AZD1656, a glucokinase activator, in a preclinical model of systemic lupus erythematosus (SLE). This collaboration aims to generate high-quality preclinical data to guide...
by | Feb 24, 2025 | Lupus Foundation of America
March is here, and as we observe Kidney Month, it’s crucial to raise awareness about how lupus can severely impact the kidneys. Did you know that up to 60% of people with lupus will develop lupus-related kidney disease, known as lupus nephritis? It’s so important for...
by | Feb 21, 2025 | Lupus Foundation of America
“Not even water?” This is one of the most common questions Muslims receive when fasting during Ramadan. No, we cannot eat or drink while fasting. But Ramadan is the most beautiful and awaited month of the year for Muslims. However, for individuals with chronic health...
by | Feb 21, 2025 | Lupus Foundation of America, News & Events
People with systemic lupus erythematosus (SLE) often face irreversible organ damage due to uncontrolled disease activity, frequent disease flares, and long-term glucocorticoid treatment. A recent study evaluated the effectiveness of anifrolumab (Saphnelo®) combined...
by | Feb 7, 2025 | Lupus Foundation of America, News & Events
The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to Adicet Bio’s ADI-001 for refractory systemic lupus erythematosus (SLE) with extrarenal involvement (when a disease affects organs outside of the kidneys, like the heart, liver or...
by | Feb 7, 2025 | Lupus Foundation of America, News & Events
The New England Journal of Medicine has published a detailed analysis of Genentech’s positive results from the Phase III REGENCY study of Gazyva® (Obinutuzumab) for people with active lupus nephritis (LN). The study was supported by the Lupus Foundation of...
